Fujifilm to Introduce Artificial Intelligence Initiative for United States Market at RSNA 2017

STAMFORD, Conn., Nov. 26, 2017 /PRNewswire/ -- FUJIFILM Medical Systems U.S.A., Inc., a leading provider of enterprise imaging and medical informatics solutions, today announces the expansion of Fujifilm's artificial intelligence (AI) development initiative with entry in the U.S. market. Fujifilm's AI development initiative will harness the power of AI to enhance its imaging and informatics healthcare Synapse® portfolio which includes Synapse PACS, Synapse Cardiovascular, and Synapse VNA among other solutions. The initiative will be on display at booth #4111 in the South Hall of McCormick Place in Chicago at the Radiological Society of North America's (RSNA).

"Fujifilm has broad experience in imaging science based on knowledge and expertise accumulated over the course of 70 years of developing image analysis and evaluation technologies. Our intention is to leverage that expertise in accelerating the delivery of powerful use cases to the AI platform we are developing," said Tak Shimomura, Chief Technology Officer at FUJIFILM Medical Systems U.S.A., Inc. "We recognize the value of closely collaborating with providers in the U.S. and envision our AI capability evolving out of this market."

The program will be based in Raleigh, North Carolina – the global development headquarters for Fujifilm's Synapse portfolio in collaboration with FUJIFILM Corporation's development team in Tokyo  that will provide a wide range of image recognition technologies. Fujifilm will partner with its strategic customers in the U.S. market, to draw upon clinical insights and expertise in the field to bridge AI applications to imaging informatics solutions.

In an increasingly complex healthcare environment with larger datasets, and rising demand for high quality care, AI will have the potential to change the practice of medicine. The AI revolution is underway and with its long history of innovation, Fujifilm is at the forefront of development to refine this disruptive technology for medical imaging and healthcare informatics.

"The timing of the expansion of the Fujifilm AI initiative in the U.S. market is significant as we recently released our latest innovation—Synapse 5 PACS. PACS, and specifically server side technology, have the potential to realize considerable positive impacts from AI in the future," said Bill Lacy, Vice President of Medical Informatics at FUJIFILM Medical Systems U.S.A., Inc. "We look forward to sharing more about this very important initiative at RSNA in Chicago."

For more information about Fujifilm or to schedule a product demonstration, please visit: http://rsna.fujimed.com.

About Fujifilm
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women's health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. TeraMedica Division delivers healthcare informatics, and is the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit www.fujimed.com and www.fujifilmendoscopy.com.

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies.  In the year ended March 31, 2017, the company had global revenues of $20.7 billion, at an exchange rate of 112 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

All product and company names herein may be trademarks of their registered owners.

View original content with multimedia:http://www.prnewswire.com/news-releases/fujifilm-to-introduce-artificial-intelligence-initiative-for-united-states-market-at-rsna-2017-300561312.html

SOURCE FUJIFILM Medical Systems U.S.A., Inc.